FDA approves supplemental application for Glenmark's Ryaltris nasal spray

The FDA approved a supplemental application for Ryaltris, a nasal spray combining mometasone furoate and olopatadine hydrochloride, according to the agency's drug approval database. The record lists the product as a metered spray formulation with mometasone furoate at 0.025 mg per spray and olopatadine hydrochloride at 0.665 mg per spray.¹

The submission is classified as an efficacy supplement, and its status is marked approved with a submission status date of July 7, 2026. This is the eleventh supplement filed under the application.

The sponsor of record is Glenmark Speclt, per the FDA filing. The review priority for this supplement was listed as standard.

Supporting application documents include an approval letter dated July 8, 2026, and an updated product label dated July 15, 2026, both posted to the FDA's drug approval database.

The original new drug application for Ryaltris carries the number NDA211746. No additional details on the specific clinical or manufacturing changes covered by this supplement are included in the FDA record.